Alterity Therapeutics (NASDAQ:ATHE) Trading 8.5% Higher – Still a Buy?

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) traded up 8.5% during trading on Friday . The stock traded as high as $5.50 and last traded at $5.00. 302,764 shares traded hands during mid-day trading, an increase of 110% from the average session volume of 143,874 shares. The stock had previously closed at $4.61.

Alterity Therapeutics Stock Up 8.5%

The company has a 50 day moving average of $4.32 and a 200 day moving average of $3.89.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. HB Wealth Management LLC grew its holdings in Alterity Therapeutics by 17.6% in the 1st quarter. HB Wealth Management LLC now owns 37,483 shares of the company’s stock valued at $129,000 after buying an additional 5,600 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Alterity Therapeutics in the 4th quarter valued at $108,000. Greenleaf Trust purchased a new stake in Alterity Therapeutics in the 2nd quarter valued at $70,000. Finally, BNP Paribas Financial Markets purchased a new stake in Alterity Therapeutics in the 4th quarter valued at $29,000. 2.14% of the stock is owned by institutional investors and hedge funds.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.